NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$22.15 USD
-0.98 (-4.24%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $22.17 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
NovoCure Limited [NVCR]
Reports for Purchase
Showing records 41 - 60 ( 211 total )
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
3Q22 Take: We Expect Fundamental Business to Recover in 2023; Lowering PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
2Q22 Take: Overall Business Trends Look Positive; We Do Not View LUNAR Timeline Shift as Meaningful
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Q2 Preview--LUNAR Expectations Likely to Eclipse Low Growth
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
EF-31 in Gastric "Meets Primary Endpoint" But We Don''t See a Role
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
EF-31 Phase 2 Data Suggest a Potential PFS and OS Benefit in Gastric Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Enter the Field, Stay for the Game; Initiating at Buy and $115 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E